Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published April 2018 | public
Journal Article Open

In vivo Biodistribution of Radiolabeled Acoustic Protein Nanostructures


Purpose: Contrast-enhanced ultrasound plays an expanding role in oncology, but its applicability to molecular imaging is hindered by a lack of nanoscale contrast agents that can reach targets outside the vasculature. Gas vesicles (GVs)—a unique class of gas-filled protein nanostructures—have recently been introduced as a promising new class of ultrasound contrast agents that can potentially access the extravascular space and be modified for molecular targeting. The purpose of the present study is to determine the quantitative biodistribution of GVs, which is critical for their development as imaging agents. Procedures: We use a novel bioorthogonal radiolabeling strategy to prepare technetium-99m-radiolabeled ([99mTc])GVs in high radiochemical purity. We use single photon emission computed tomography (SPECT) and tissue counting to quantitatively assess GV biodistribution in mice. Results: Twenty minutes following administration to mice, the SPECT biodistribution shows that 84 % of [99mTc]GVs are taken up by the reticuloendothelial system (RES) and 13 % are found in the gall bladder and duodenum. Quantitative tissue counting shows that the uptake (mean ± SEM % of injected dose/organ) is 0.6 ± 0.2 for the gall bladder, 46.2 ± 3.1 for the liver, 1.91 ± 0.16 for the lungs, and 1.3 ± 0.3 for the spleen. Fluorescence imaging confirmed the presence of GVs in RES. Conclusions: These results provide essential information for the development of GVs as targeted nanoscale imaging agents for ultrasound.

Additional Information

© World Molecular Imaging Society 2017. First Online: 27 September 2017 Funding Information: JLF, MY, AF, MS, and SF acknowledge the financial support of the National Institutes of Health (NIH 1R01EB018975) and the Canadian Institutes for Health Research (CIHR MOP136842). AZ, HB, NJ, and JV acknowledge the financial support of Canadian Cancer Society (Innovation grant 2015:703857) and the Canadian Institutes for Health Research (CIHR/NSERC CHRP Grant 2016: 493840-16). All experimental procedures were approved by the Animal Care Committees at Sunnybrook Research Institute and McMaster University. The authors declare that they have no conflict of interest.

Attached Files

Supplemental Material - 11307_2017_1122_MOESM1_ESM.pdf

Supplemental Material - 11307_2017_1122_MOESM2_ESM.avi

Supplemental Material - 11307_2017_1122_MOESM3_ESM.avi

Accepted Version - nihms978824.pdf


Files (7.1 MB)
Name Size Download all
4.3 MB Download
1.4 MB Preview Download
197.7 kB Preview Download
1.2 MB Download

Additional details

August 19, 2023
August 19, 2023